Versus. Cancer genomics Competitive Analysis

Transcription

1 Cancer genomics Competitive Analysis Versus

2 AGH Competitor #1 MYRIAD GENETICS, INC. Headquarters: UT, USA & Switzerland Publicly Traded Company - MYGN Founded: 1992 Company Size: employees (source: LinkedIn, dated June 20, 2016) Test for a broader gene list and cover more cancers Quicker turnaround time Offers pharmacogenomics and toxicology testing Offers collectors Cystic Fibrosis testing Cancer Panel: Test for 25 Genes across over 8+ Cancers APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53 *Highlighted genes are not tested by Aeon. Turanaround Time is 2-6 Weeks Myriad s Competitive Advantages: Extensive diagnostic pipeline across the disease spectrum Blood and buccal swab testing Offer: lung cancer molecular diagnostic test and rheumatoid arthritis multi-biomarker molecular blood test First in breast cancer genetic testing Superior genetic mutations database for breast and ovarian cancer; have tested 2 million patients. Considered a leader in the breast cancer testing market and provide extensive education on the topic of hereditary cancer genetics testing, have an extensive academic collaboration list, and actively engage with leading industry companies. Involved in clinical trials testing. Partnerships (companion diagnostics collaboration companies): AstraZeneca Drug: Olaparib phase 3 clinical studies; received U.S. FDA and EMA approval for maintenance therapy platinum sensitive ovarian cancer in CY2014 and expect to file with the FDA for breast cancer in CY16. Medivation Drug: Talazoparib phase 3 metastatic breast cancer clinical study. Drug: Talazoparib research collaboration on mychoice HRD panel. TESARO Drug: Niraparib phase 3 maintenance therapy for platinum sensitive ovarian cancer and metastatic breast cancer. Timeline: Q2 CY16 (2016). Drug: Niraparib phase 3 maintenance therapy for platinum. Timeline: Q2 CY16. Abbvie Drug: Veliparib phase 3 clinical trials in neo-adjuvant and metastatic breast cancer. Drug: Veliparib research collaboration on mychoice HRD panel. Other Partnerships: Abbott, AstraZeneca, Bristol-Myers Squibb, Celgene, GSK, Johnson-Johnson, Lilly, Merck, Novartis, Roche, Sanofi, and Tesaro.

3 AGH Competitor #2 PATHWAY GENOMICS Headquarters: San Diego, CA Privately Held Founded: 2008 Company Size: employees (source: LinkedIn, dated June 21, 2016) CancerNext-Expanded Panel: Test for 18 Genes across over 3+ Cancers APC, BRCA1, BRCA2, BMPR1A, CDH1, CHEK2, EPCAM, MDM2-SNP309, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, PTEN, SMAD4, STK11, TP53. *Highlighted genes are not tested by Aeon. Turanaround Time is 2-3 weeks. Test for a broader gene list and cover more cancers Quicker turnaround time Offers pharmacogenomics and toxicology testing Offers collectors Offers Cystic Fibrosis testing Collaborations with universities across the US USC UNG Emory University Pathway Genomics Competitive Advantages: Offer tests in areas that are not offered by Aeon, which include: General Health & Wellness: Cardiac, fitness and weight, and skin health testing Liquid Biopsy Also offer Pharmacogenomics test Carrier Screening Test Blood and buccal swab testing Global translation web pages: Spanish, Russian, Portuguese, French, etc. (7 languages total) Presence in the state of New York Offers direct to consumer services through their online physician access portal and through a patient s physician. Have an established program with IBM Watson merging of artificial intelligence and deep learning with precision medicine. Have an established phone application for accessing reports.

4 AGH Competitor #3 AMBRY GENETICS Headquarters: Aliao Viejo, CA Privately Held Founded: 1999 Company Size: employees (source: LinkedIn, dated June 21, 2016) CancerNext-Expanded Panel: Test for 49 Genes across over 25+ Cancers APC, ATM, BAP1, BARD1, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FH, FLCN, GREM1, MAX, MEN1, MET, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TMEM127, TP53, TSC1, TSC2, VHL. *Highlighted genes are not tested by Aeon. Turnaround Time for the CancerNext-Expanded Panel is 2-3 weeks. Quicker turnaround times Offer pharmacogenomics and toxicology testing Offer collectors Offer Cystic Fibrosis testing Collaborations with Universities across the US USC UNG Emory University Ambry Genetics Competitive Advantages: Offers a more expanded gene list. Offer all genes Aeon includes plus additional 12 genes (highlighted* on the left list). Offers Hereditary Cardiovascular Testing General Genetic Testing Neurology Genetic Testing Offers Microarray options for detection of DNA rearrangements, including 180k Oligo Array and an enhance option, the SNP Array Offers exome sequencing tests designed specifically for establishing neonatal, pediatric, adult-onset, and prenatal genetic diagnosis Ambry Genetics and prominent oncology research collaborators to share new hereditary cancer data at an American Society of Clinical Oncology (ASCO) annual meeting (June 3-7, 2016). Two Ambry abstracts have been accepted to be published in a Journal of Clinical Oncology supplement. Ambry s dedication to scientific collaboration and data sharing is emphasized through its AmbryShare program sharing one of the largest genome (exome) disease databases, containing aggregated anonymous data from 10,000 human genome(s). This data is estimated to triple the collective knowledge of genetics and many human diseases. New Super Lab unveiled at 65,000-square-feet (February 18, 2016); they are estimating to triple the number of patient samples processed daily, though the Super Lab was designed to increase capacity from current by nine fold.

5 AGH Competitor #4 LABCORP INTEGRATED GENETICS (VistaSeq SM) Headquarters: Burlington, NC Public Company: LH Cancer Panel: Test for 27 Genes across over 8+ Cancers APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRKAR1A, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53. *Highlighted genes are not tested by Aeon Specimen Type: Whole Blood 10mL volume (adult) and 7mL volume (pediatric). Test Introduced: 2015 Founded: 1978 Company Size: 48,000+ employees worldwide (source: LabCorp website, dated July 19, 2016) Turnaround Time is 2-3 weeks. Quicker turnaround time Offer pharmacogenomics and toxicology testing. Offer collectors Oral swab method vs. blood collection less invasive and our test can be provided to hemophilia population 20,000 in the US(according to the CDC) CGx report is easier to read LabCorp. s Competitive Advantages: Offers a larger panel for hereditary carrier screen testing (not hereditary cancer related) 142 genes across 114 different inherited diseases, while Aeon only offers the Cystic Fibrosis at this time. Have been in the industry for 25+ years performing complex, high-demand testing services Offer a broader range of services including PGx and Tox In-network with a larger number of providers Have performed DNA tests in support of more than 2 million legal cases. Hold many patents in the US, Canada, and Europe. Integrates with numerous electronic medical record systems (EMR) and practice management systems (PMS). Install a bridge to automate the transfer of current patient demographic information. LabCorp has combined Covance s drug development leadership and LabCorp s medical testing expertise to build a market leader in both central laboratory and bioanalysis services. Roots of the company extend back to 1905 when Hoffmann-La Roche began operations in the US. In December 2010, completed the acquisition of Genzyme Genetics providing reproductive and oncology testing services, renamed in January 2012 to Integrated Genetics for the reproductive portion of Genzyme Genetics business. Have 48,000 employees in over 60 countries, serving more than 220,000 clients, including physicians, biopharmaceutical companies, government agencies, managed care organizations, hospitals, and clinical labs.

6 AGH Competitor #5 QUEST DIAGNOSTICS Headquarters: Madison, NJ Public Company: DGX Cancer Panel: MYvantage - comprehensive test Test for 34 Genes across over 15 Cancers APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MEN1, MLH1, MSH2, MSH6, MUTYH, NBN, NF1 PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, RET, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, VHL. *Highlighted genes are not tested by Aeon Specimen Type: Blood Test Introduced: in 2015 Founded: 1967 Company Size: 44,000+ employees worldwide (source: Quest website, dated July 19, 2016) Test for more genes and cancers Offer collectors Oral swab method vs. blood collection less invasive and our test can be provided to the hemophilic population 20,000 in the US (according to the CDC) CGx report is easier to read More involved with University Collaborations Quest s Competitive Advantages: Have been in the industry for 25+ years performing complex, high-demand testing services Offer a broader range of services including PGx and Tox most other services offered through partnered companies In-network with a larger number of providers. Involved in development and manufacture of devices Turanaround Time is 2 weeks. Won gold Medical Design Excellence Award (MDEA) for diagnostic innovation in First FDA-cleared molecular test and kit for 2009 H1N1 flu pandemic. First laboratory-developed test for West Nile Virus. Offer type-specific HSV testing used to help diagnose herpes and to distinguish between the two types of herpes infection HSV-1 and HSV2. The 4myheart program provides personalized care to help patients improve their cardiac health. A clinical educator addresses the patient s risk for heart disease and stroke, using the test results and a treatment plan from the patient s doctor. Quiggles Wiggles is a phlebotomy device for children and patients of all ages featuring a soothing combination of ice pack and vibration. This makes the draw feel more comfortable for everyone, including little ones, their parents, and adults alike. First national lab to employ specimen tracking, enhancing customer service. By assigning unique bar codes and using handheld scanners, can follow a patient specimen at every step of its journey to and through the laboratory.